TACSTD2 (Tumor Associated Calcium Signal Transducer 2)

P3, N=1170, Active, not recruiting, Daiichi Sankyo | Trial completion date: Aug 2027 --> May 2029 | Trial primary completion date: Aug 2027 --> May 2029

Additionally, we optimized the rapid incubation imaging method (RIIM) by shortening the procedure to less than 8 min, illustrating TTP-ICG's high performance in distinguishing malignant from normal tissues/fibroadenoma lesions as well as detecting metastatic lymph nodes in a cohort of 59 patients. Thus, this TROP2-targeting probe demonstrates its significance for fluorescence imaging-guided surgery with dual applicability in EBC, providing translational potential for further clinical decision-making.

With the recent FDA-approval of sacituzumab govitecan and datopotamab deruxtecan in breast cancer, TROP2-targeting therapies showed promising clinical outcomes. This work represents only analytic validation, but work on clinical validation has begun. In the future, this assay may help identify patients who are more likely to benefit from TROP2-targeted therapies.

P2, N=50, Active, not recruiting, Yale University | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

Our findings underscore the clinical significance of TROP2 expression in UTUC and suggest that IHC-based evaluation may contribute to prognostic risk stratification.

Notably, a subset of patients exhibits high expression in tumor tissue, accompanied by low expression in adjacent non-tumor urothelium, suggesting a favorable therapeutic index for antibody-drug conjugate therapy. These findings support the need for further biomarker-driven studies to optimize patient selection and treatment outcomes.

Patients being refractory to ≥2 lines of prior therapy and an irinotecan-free interval of at least 6 months are enrolled. The primary endpoint is progression-free survival. TROPHIT1 contains a translational research program to unravel the determinants of resistance.

This study demonstrated that GPC3 CAR-T. TROP2 BiTE was a potent therapy for LUSC and provided a strategy for overcoming the antigen heterogeneity in solid tumors.

In a humanized NSCLC mouse model, the fusion protein achieved significant tumor growth inhibition and delayed tumor progression. Collectively, these findings highlight the potential of vGY2-IL-15sa for targeted cancer immunotherapy and establish a compact VNAR-based immunocytokine platform, offering a promising approach to enhancing the therapeutic effects of IL-15 while minimizing toxicity.

P2, N=25, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

Among patients undergoing nivolumab treatment, CPS ≥1 was significantly associated with longer survival outcomes in CLDN18.2-positive patients, and a tendency toward improved Nivo-OS in TROP2-positive patients.

Here, we provide several direct and pretargeted radiopharmaceutical variants yielding therapeutic benefit for a Trop-2.2 expressing pancreatic cancer model.